Asian Stocks Slip as Oil Rebounds Amid Fed Rate Hike Fears 
Yen Near 40-Year Low as USD/JPY Approaches Key 162 Level, Raising Intervention Concerns 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Wall Street Ends Mixed as Tech Stocks Struggle Ahead of Micron Earnings 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Wall Street Slides as AI Stocks Tumble Following South Korea Tech Sell-Off 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Oil Prices Slip as Iran Sanctions Relief and Hormuz Shipping Recovery Ease Supply Concerns 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
US Dollar Climbs to One-Year High as Fed Rate Hike Expectations Surge 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
South Korea Stocks Tumble as AI-Fueled Rally Faces Profit-Taking Pressure 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Samsung Biologics and AstraZeneca are reportedly dissolving their biosimilar joint venture. They have formed the Archigen Biotech for the JV, and now this is being shut down.
An official of Samsung Biologics, the biotech unit of the Samsung Group, said on Tuesday, May 24, that it has decided to end its joint venture with the British-Swedish multinational pharmaceutical and biotechnology company due to the suspension of the development of a biosimilar product.
According to Yonhap News Agency, the decision came two months after the Samsung Biologics’ board agreed with the liquidation of Archigen Biotech Ltd. The said company was set up in 2014 via a 50-50 joint venture with AstraZeneca.
When it was first established, Archigen Biotech was working on the development of SAIT101, a biosimilar of Rituximab, a monoclonal antibody medication used for the treatment of lymphoma. It was explained that a biosimilar is a similar duplication of an already existing and approved biologic drug.
However, both Samsung Biologics and AstraZeneca halted the biosimilar program and scrapped the Rituxan copy project. It was revealed to have been actually discontinued in the second half of 2020 after competitors such as Celltrion Inc. started marketing the same products.
Fierce Pharma further reported that Archigen Biotech already launched a phase 3 trial of the SAIT101 in June 2016, but the works have been progressing very slowly. In fact, the original target date for the completion of the project has already been pushed back by more than a year.
The results of the trial were revealed last month and showed that the Rituxan biosimilar medication generated a response in 66.3% of patients, which is on par with the 70.6% posted by the originator.
But then, another issue has cropped up - the market for this product is already crowded with other biotech firms introducing their own biosimilars, with some already being sold. Aside from Celltrion, Achigen Biotech is also competing with Teva Pharmaceuticals, Pfizer, Mylan, and Novartis’ Sandoz. With all of these firms, it became apparent to Samsung Biologics and AstraZeneca that the best move now is to scrap their own Rituxan biosimilar product.
